Bortezomib Injection (Shilpa)

硼替佐米注射液 (Shilpa)

Report date: 2025/04/28 22:35:30

Base Information

Drug NameBortezomib Injection (Shilpa)
Drug Alias NameBORUZU
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProteasome inhibitors
TargetsProteasome
Therapy Area/IndicationsMultiple MyelomaLymphoma, Mantle-Cell
Global Approved IndicationsMultiple MyelomaLymphoma, Mantle-Cell
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/09/05
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesShilpa Medicare Ltd
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsMultiple MyelomaLymphoma, Mantle-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A